Covering all aspects of the pharma industry and across all therapeutic areas, Kevin has interviewed pretty much all the leading figures in the sector. A regular attendee at financial and medical conferences (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss the industry. Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at Catholic newspaper The Universe and contributed articles to the likes of The Independent and the Manchester Evening News on football.
Latest from Kevin Grogan
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
Multi-blockbuster falls short in a giant cell arteritis study.
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.
Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.
Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.
The biotech had been looking at options to survive since May.